ArticleGastroenterology research and practice2018
Gastric Cancer Maximum Tumour Diameter Reduction Rate at CT Examination as a Radiological Index for Predicting Histopathological Regression after Neoadjuvant Treatment: A Multicentre GIRCG Study.
Article in Gastroenterology research and practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- CT acquisition protocols by pathology, SIRM position paper part 2 (Abdominal and Oncologic Imaging, Urology, Paediatric).La Radiologia medica · 2026Guideline
- Discordance in tumour response assessment for gastric cancer after neoadjuvant chemotherapy using different methods.Abdominal radiology (New York) · 2026Article
- Endoscopic combined esophageal semi-tunnel and gastric exposed resection for a large transesophagogastric leiomyoma: a case report.Frontiers in medicine · 2026Article
- International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape : Bertinoro Workshop, November 2022.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024Article
- Imaging advances in efficacy assessment of gastric cancer neoadjuvant chemotherapy.Abdominal radiology (New York) · 2023Review
- The role of computed tomography features in assessing response to neoadjuvant chemotherapy in locally advanced gastric cancer.BMC cancer · 2023Article
- Association between Pre-Treatment Biological Indicators and Compliance to Neoadjuvant/Perioperative Chemotherapy in Operable Gastric Cancer.Nutrients · 2023Article
- Article
- Some Concerns from a Radiological Point of View. Comment on Huang et al. Outcomes of Conversion Surgery for Metastatic Gastric Cancer Compared with In-Front Surgery Plus Palliative Chemotherapy or In-Front Surgery Alone.Journal of personalized medicine · 2022Article
- Structured and shared CT radiological report of gastric cancer: a consensus proposal by the Italian Research Group for Gastric Cancer (GIRCG) and the Italian Society of Medical and Interventional Radiology (SIRM).European radiology · 2022Article
- Down-staging depth score could be a survival predictor for locally advanced gastric cancer patients after preoperative chemoradiotherapy.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2021Article
- The value of restaging CT following neoadjuvant chemotherapy for resectable gastric cancer. A population-based study.World journal of surgical oncology · 2021Article
- Delta-radiomics and response to neoadjuvant treatment in locally advanced gastric cancer-a multicenter study of GIRCG (Italian Research Group for Gastric Cancer).Quantitative imaging in medicine and surgery · 2021Article
- Gastrointestinal Applications of Iodine Quantification Using Dual-Energy CT: A Systematic Review.Diagnostics (Basel, Switzerland) · 2020Review
- Gastrointestinal stromal tumors (GIST): a proposal of a "CT-based predictive model of Miettinen index" in predicting the risk of malignancy.Abdominal radiology (New York) · 2020Article
- STAMBPL1 knockdown has antitumour effects on gastric cancer biological activities.Oncology letters · 2019Article
- Update in diagnostic imaging of the thymus and anterior mediastinal masses.Gland surgery · 2019Review
- The role of delta radiomics in gastric cancer.Quantitative imaging in medicine and surgery · 2018Article
- T and N Staging of Gastric Cancer Using Dual-Source Computed Tomography.Gastroenterology research and practice · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the role of maximum tumour diameter (D-max) reduction rate at CT examination in predicting histopathological tumour regression grade (TRG according to the Becker grade), after neoadjuvant chemotherapy (NAC), in patients with resectable advanced gastric cancer (AGC). MATERIALS AND
methodsEighty-six patients (53 M, mean age 62.1 years) with resectable AGC (≥T3 or N+), treated with NAC and radical surgery, were enrolled from 5 centres of the Italian Research Group for Gastric Cancer (GIRCG). Staging and restaging CT and histological results were retrospectively reviewed. CT examinations were contrast enhanced, and the stomach was previously distended. The D-max was measured using 2D software and compared with Becker TRG. Statistical data were obtained using "R" software.
resultsThe interobserver agreement was good/very good. Becker TRG was predicted by CT with a sensitivity and specificity, respectively, of 97.3% and 90.9% for Becker 1 (D-max reduction rate > 65.1%), 76.4% and 80% for Becker 3 (D-max reduction rate < 29.9%), and 70.8% and 83.9% for Becker 2. Correlation between radiological and histological D-max measurements was strongly confirmed by the correlation index (c.i.= 0.829).
conclusionsD-max reduction rate in AGC patients may be helpful as a simple and reproducible radiological index in predicting TRG after NAC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.